The 101 on Oral Therapies for COVID-19

Two oral therapies for COVID-19 were recently approved. Listen in as we discuss who is eligible to receive them, their efficacy, and what this means for the future of COVID-19 treatment.Guest: Patrick Kinn, PharmD, MPH, BCPSClinical Pharmacy Specialist - Infectious DiseaseUniversity of Iowa Health CareJohn A. Galdo, PharmD, MBA, BCPS, BCGP (Jake)Course Content and Developer, CEimpactPharmacist, Ross Bridge PharmacyCEO, Seguridad, IncRedeem your CPE or CME credit here!Pharmacist members CMENeed a membership?Join for CPE Credit Join for CME Credit References and resources: Jayk BA, Gomes da Silva MM, Musungaie DB, et al. MOVe-OUT Study Group. Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients. N Engl J Med. 2021 Dec 16:NEJMoa2116044. doi: 10.1056/NEJMoa2116044. Epub ahead of print. PMID: 34914868; PMCID: PMC8693688.PAXLOVID (nirmatrelvir) [Emergency Use Authorization]. U.S. Food and Drug Administration website. Published December 22, 2021. Accessed January 5, 2021. https://www.fda.gov/media/155050/downloadLiverpool COVID-19 Interactions. https://www.covid19-druginteractions.org/COVID-19 Public Therapeutic Locator. https://healthdata.gov/Health/COVID-19-Public-Therapeutic-Locator/rxn6-qnx8/dataContinuing Education Information:Learning Objectives: Identify the eligible population for treatment of COVID-19 with oral therapyDiscuss the efficacy of currently available oral therapy treatment options for COVID-19Dr. Wall is a member of the Janssen Speaker's Bureau. Dr. Galdo reports no actual or potential conflicts of interest associated with this episode.Dr. Kinn reports no actual or potential conflicts of interest associated with this episode.0.05 CEU | 0.5 HrsACPE UAN: 0107-0000-22-056-H01-PInitial release date: 01/17/22Expiration date: 01/17/2023Additional CPE & CME details can be found hereFollow CEimpact on Social Media:LinkedInInstagram